Bay Area biotech SonoThera is bubbling to a clinical boil after raising a
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
SonoThera raises $125M for non-viral gene therapy approach
Gilead and Merck's latest trial success and flop
Genentech and Novartis dish up food allergy microdrama series
J&J eyes rare disease expansion for blockbuster-to-be Imaavy with trial win
City Therapeutics gets $99M to gather data on three RNAi medicines
Small Biotech Catapults To Record High On $10.6 Billion Deal
Sophia Genetics, Memorial Sloan Kettering sign strategic collab for AI-powered precision oncology hub
AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine
SonoThera has secured another $125 million to take its ultrasound-based gene therapy technology into the clinic.
With phase 3 results that have “exceeded” BioMarin’s expectations, according to R&D chief Greg Friberg, M.D., the California…
Modern drug development demands faster, more scalable gene expression insights. Download this white paper to explore how…
Bristol Myers Squibb is the latest large pharma company to be making a major bet on artificial intelligence,
As China-developed assets gain more attention from biopharma dealmakers, some industry watchers want to cur | As China-developed…
Merck & Co. and Kelun-Biotech's sac-TMT is on fire this week with details or first reports of three positive phase 3 trials. |…
